NCT01814553 - ADAM-Afatinib Diarrhea Assessment and Management | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

afatinib

Daily treatment starting 40 mg per day

DRUG

loperamide

Follow cohort assignment and diarrhea management guidelines

Trial Locations (12)

1200.167.01009 Boehringer Ingelheim Investigational Site, Santa Rosa

1200.167.01020 Boehringer Ingelheim Investigational Site, Orlando

1200.167.01018 Boehringer Ingelheim Investigational Site, Port Saint Lucie

1200.167.01012 Boehringer Ingelheim Investigational Site, St. Petersburg

1200.167.01007 Boehringer Ingelheim Investigational Site, Skokie

1200.167.01008 Boehringer Ingelheim Investigational Site, Skokie

1200.167.01001 Boehringer Ingelheim Investigational Site, Morristown

1200.167.01014 Boehringer Ingelheim Investigational Site, Corvallis

1200.167.01002 Boehringer Ingelheim Investigational Site, Chattanooga

1200.167.01006 Boehringer Ingelheim Investigational Site, Chattanooga

1200.167.01005 Boehringer Ingelheim Investigational Site, Nashville

1200.167.01003 Boehringer Ingelheim Investigational Site, Richmond